滲出型加齢黄斑変性に対するラニビズマブ硝子体内投与の成績

Outcome of intravitreal ranibizumab for age-related macular degeneration

要約　目的：滲出型加齢黄斑変性（AMD）に対するラニビズマブ硝子体内投与の治療成績の報告。対象と方法：過去12か月間にラニビズマブ硝子体内投与を行った94例97眼を対象とした。平均年齢は74.9±9.3歳で，典型的AMDが68眼，ポリープ状脈絡膜血管症が21眼，網膜血管腫状増殖が8眼であった。視力はlogMARで評価し，0.3以上の変化を改善または悪化とした。全例で6か月以上の経過を追った。結果：術前平均視力は0.68±0.40，術後の最高平均視力は0.41±0.40で，有意差があった（p＜0.05）。光干渉断層計で測定した中心窩網膜厚は有意に減少した（p＜0.05）。経過中に光線力学的療法を14眼に行った。結論：AMDに対するラニビズマブ硝子体内投与後6か月間に，平均視力が有意に改善し，中心窩網膜厚が有意に減少した。

Abstract.　Purpose：To report the outcome of intravitreal injection of ranibizumab for exudative age-related macular degeneration（AMD）. Cases and Method：This retrospective study was made on 97 eyes of 94 cases of AMD who received intravitreal injection of ranibizumab during the past 12 months. The age averaged 74.9±9.3 years. The series comprised 68 eyes of typical AMD,21 eyes of polypoidal choroidal vasculopathy,and 8 eyes of retinal angiomatous proliferation. Visual acuity was evaluated as logMAR. Cases were followed up for 6 months or longer. Results：The mean of postoperative best collected visual acuity was 0.41±0.40 with statistically significant improvement as compared with preoperative values（0.68±0.40）（p＜0.05）. Central retina thickness was significantly decreased（p＜0.05）. Photodynamic therapy was performed on 14 eyes during the follow-up period. Conclusion：Intravitreal injection of rabinizumab was followed by significantly improved visual acuity and decreased foveal thickness in eyes with AMD during the following 6 months.